Furthermore, Zhu et al. reported the first association between miR-126 expression and cancer chemotherapy; the team found that enhanced miR-126 expression increases the sensitivity of NSCLC cells to therapy through negative regulation of the VEGF-A/PI3K/Akt/multidrug resistance protein 1 (MRP1) pathway. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.